Lobeline for smoking cessation.
BACKGROUND
Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking.


OBJECTIVE
The objective of this review was to assess the effects of lobeline on long term smoking cessation.


METHODS
We searched the Cochrane Tobacco Addiction Group trials register.


METHODS
Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up.


METHODS
We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up.


RESULTS
We identified no trials meeting the full inclusion criteria including long term follow-up.


CONCLUSIONS
There is no evidence available from long term trials that lobeline can aid smoking cessation.
Stead
L F
LF
ICRF General Practice Research Group, Division of Public Health and Primary Health Care, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF. lindsay.stead@dphpc.ox.ac.uk
Hughes
J R
JR
D006801:Humans; D008120:Lobeline / Q000627:therapeutic use*; D018733:Nicotinic Antagonists / Q000627:therapeutic use*; D016540:Smoking Cessation; D000074606:Smoking Prevention
D018733:Nicotinic Antagonists; D008120:Lobeline